339 WHY OVER-THE-SCOPE-CLIP IS POTENTIALLY MORE EFFECTIVE THAN STANDARD ENDOSCOPIC HEMOSTASIS AS PRIMARY TREATMENT OF SEVERE NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING

2019 ◽  
Vol 89 (6) ◽  
pp. AB72 ◽  
Author(s):  
Dennis M. Jensen ◽  
Thomas O. Kovacs ◽  
Kevin A. Ghassemi ◽  
Marc Kaneshiro ◽  
Gareth Dulai ◽  
...  
Endoscopy ◽  
2016 ◽  
Vol 48 (S 01) ◽  
pp. E22-E23
Author(s):  
Marco D’Assunçao ◽  
Paul Kröner ◽  
Ujjwal Kumar ◽  
Juan Gutierrez ◽  
Lucia Fry ◽  
...  

2010 ◽  
Vol 22 (2) ◽  
pp. 151-155 ◽  
Author(s):  
Mikinori Kataoka ◽  
Takashi Kawai ◽  
Kenji Yagi ◽  
Chizuko Tachibana ◽  
Hiroyuki Tachibana ◽  
...  

2009 ◽  
Vol 54 (11) ◽  
pp. 2418-2426 ◽  
Author(s):  
Shou-jiang Tang ◽  
Sun-Young Lee ◽  
Linda S. Hynan ◽  
Jingsheng Yan ◽  
Fransell C. Riley ◽  
...  

Endoscopy ◽  
2019 ◽  
Vol 51 (05) ◽  
pp. 458-462 ◽  
Author(s):  
Jin-Seok Park ◽  
Byung Wook Bang ◽  
Su Jin Hong ◽  
Eunhye Lee ◽  
Kye Sook Kwon ◽  
...  

Abstract Background A new hemostatic adhesive powder (UI-EWD) has been developed to reduce the high re-bleeding rates associated with the currently available hemostatic powders. The current study aimed to assess the efficacy of UI-EWD as a salvage therapy for the treatment of refractory upper gastrointestinal bleeding (UGIB). Methods A total of 17 consecutive patients who had failed to achieve hemostasis with conventional endoscopic procedures and had undergone treatment with UI-EWD for endoscopic hemostasis in refractory UGIB were prospectively enrolled in the study. We evaluated the success rate of initial hemostasis and rate of re-bleeding within 30 days. Results All patients underwent successful UI-EWD application at the bleeding site. Initial hemostasis occurred in 16/17 patients (94 %). Re-bleeding within 30 days occurred in 3/16 patients (19 %) who had achieved initial hemostasis. In the second-look endoscopy after 24 hours, hydrogel from UI-EWD was found attached at the bleeding site in 11/16 patients (69 %). Conclusion UI-EWD has a high success rate for initial hemostasis in refractory UGIB and shows promising results in the prevention of re-bleeding.


2017 ◽  
Vol 05 (11) ◽  
pp. E1159-E1164 ◽  
Author(s):  
Oscar Cahyadi ◽  
Markus Bauder ◽  
Benjamin Meier ◽  
Karel Caca ◽  
Arthur Schmidt

Abstract Background and study aims TC-325 (Hemospray, Cook Medical) is a powder agent for endoscopic hemostasis in patients with upper gastrointestinal bleeding (UGIB). Although most publications are based on case-reports and retrospective studies, data on efficacy are promising. Here we report our experience with TC-325 for diffuse or refractory UGIB. Patients and methods Data on patients receiving TC-325 for endoscopic hemostasis from November 2013 to February 2017 at our center were analyzed retrospectively. Primary endpoints were technical success (successful immediate hemostasis) and clinical success (effective hemostasis and no recurrent bleeding). Secondary endpoints were recurrent bleeding within 3 and 7 days, hospital mortality and TC-325 associated complications. TC-325 was used for bleeding not amenable to standard endoscopic treatment (e. g. diffuse bleeding) or as salvage therapy after failure of conventional methods Results Fifty-two patients received TC-325 treatment. Most of the patients were treated for peptic ulcer bleeding (18/52 patients, 34.6 %) and post-interventional bleeding (13/52 patients, 25 %). Hemospray was used in 23/52 (44.2 %) patients as monotherapy and in 29/52 (55.8 %) patients as a salvage therapy. Application of the powder on the bleeding source was successful in all patients with no therapy-related adverse events (AEs). Immediate hemostasis was achieved in 51/52 (98.1 %) patients. Recurrent bleeding within 3 and 7 days was observed in 22/51 and 25/51 patients respectively (43.1 % and 49 %). The overall clinical success was 56.9 % on day 3 and 51 % on day 7. Total mortality was 15.4 % (8 patients), bleeding associated mortality was 3.8 % (2 patients). There were no therapy-related AEs. Conclusions TC-325 showed a high technical success rate as monotherapy for bleeding sources not amenable to standard methods or as an “add-on” therapy after unsuccessful hemostasis. However, rebleeding was frequent in this cohort and further studies are warranted to exactly define a treatment algorithm for TC-325 use.


2014 ◽  
Vol 79 (5) ◽  
pp. AB143
Author(s):  
Matthew J. Skinner ◽  
Juan P. Gutierrez ◽  
Helmut Neumann ◽  
Chad M. Burski ◽  
C. Mel Wilcox ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document